Abstract: Lichens, prurigos, pruriginous toxidermias and/or severe pruritus afflicting a mammalian, notably human patient, are therapeutically treated by administrating to such patient a therapeutically/cosmetically effective amount of at least one CGRP antagonist, advantageously in combinatory immixture with at least one antagonist of a neuropeptide other than CGRP, e.g., a substance P antagonist, and/or at least one inflammation mediator antagonist.

Abstract: Cosmetic/pharmaceutical/hygienic compositions (e.g., lipcolors) are formulated as homogeneous and stable, supple dough extrudates, said supple dough extrudates having at least one thermally-unmodified but normally heat-sensitive compound (for example a volatile compound and/or a compound having a low flash point) and at least one elevated melting temperature T compound (for example a wax) homogeneously distributed therethrough.

Abstract: Topically applicable cosmetic/dermatological composition well suited for improved photoprotection of human keratinous substrates, for example human skin and/or hair, comprise (a) an aqueous phase, (b) at least one fatty phase having a refractive index n.sub.1, (c) an effective UV-photoprotecting amount of at least one water-soluble UV-screening active agent, and (d) particulates of at least one non-film- forming polymer having a refractive index n.sub.2, and the refractive indices n.sub.1, and n.sub.2 being selected such that:.vertline.n.sub.2 -n.sub.1 .vertline..ltoreq.0.07.

Abstract: Skin redness, rosacea and/or discreet erythema afflicting a mammalian, notably human patient, are therapeutically treated by administrating to such patient a therapeutically/cosmetically effective amount of at least one CGRP antagonist, advantageously in combinatory immixture with at least one antagonist of a neuropeptide other than CGRP, e.g., a substance P antagonist, and/or at least one inflammation mediator antagonist.

Abstract: Topically applicable dermocosmetic compositions for whitening/depigmenting human skin, comprise a skin-whitening/depigmenting effective amount of at least one melatonin derivative having the structural formula (I): in which R.sub.1 is a lower alkyl radical, R.sub.2 is a hydrogen atom or a lower alkyl radical, and R.sub.3 is a hydrogen atom or a lower acyl radical, with the proviso that the hydroxyl radical is in the 4-, 6- or 7-position on the indole ring system, or a physiologically acceptable salt, solvate or bioprecursor/prodrug thereof, formulated into a topically applicable, cosmetically/dermatologically acceptable vehicle, carrier or diluent therefor.

Abstract: Improvedly photostable, topically applicable cosmetic/dermatological sunscreen compositions well suited for enhanced photoprotection of human skin and/or hair against the damaging effects of UV-A and UV-B irradiation, particularly solar radiation, comprise (i) 4-tert-butyl-4'-methoxydibenzoylmethane, (ii) at least one particular 1,3,5-triazine compound, and (iii) at least one alkyl .beta.,.beta.'-diphenylacrylate or alkyl .alpha.-cyano-.beta.,.beta.'-diphenylacrylate, formulated in a cosmetically/dermatologically acceptable vehicle, diluent or carrier therefor.

Abstract: The loss of body/cranial hair is promoted and/or its growth is slowed/prevented by topically and/or systemically administering to an individual in need of such treatment respectively effective amounts at least one lipoxygenase inhibitor and at least one cyclooxygenase inhibitor, or alternatively, an effective amount of an active agent that is both a lipoxygenase inhibitor and a cyclooxygenase inhibitor.

Abstract: Photoprotective/cosmetic compositions well suited for enhanced photoprotection of human skin and/or hair, as well as of a wide variety of other photosensitive materials and substrates, e.g., inorganic or organic glasses, plastics or the like, against the deleterious effects of UV-A and UV-B irradiation, particularly solar radiation, comprise a photoprotecting effective amount of a novel insoluble benzalmalonate/phenylcyanoacrylate-substituted s-triazine compound having the structural formula (I): ##STR1## in which R.sub.1, R.sub.1 ' and R.sub.

Abstract: Dermatological/cosmetic compositions for reducing or decelerating human hair loss comprise an effective hair loss-reducing amount of combinatory immixture of (a) at least one antifungal agent and (b) at least one halogenated antibacterial agent other than a macrolide or pyranoside, characteristically formulated in a topically physiologically acceptable medium therefor.

Abstract: Cosmetic/dermatological/pharmaceutical compositions, well suited for the treatment of a variety of mammalian disorders of, for example, the skin, hair and/or mucous membranes, a manifestation of which is an excess in the synthesis and/or in the release of substance P, e.g., for the treatment of cutaneous disorders and sensitive skin, comprise an effective substance P antagonist amount of at least one salt of yttrium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, tin, manganese, or mixture thereof, in a cosmetically/pharmaceutically acceptable medium therefor.

Abstract: Dehydro-epi-androsterone sulfate, topically applied, is well suited for therapeutically treating human skin wrinkles and fine lines and/or for combating cutaneous and/or subcutaneous slackening and/or for reviving the radiance of the skin.

Abstract: Topically applicable pharmaceutical/dermatological/cosmetic compositions, well suited for the therapeutic treatment of neurogenic red skin blotches and rosacea afflicting the skin, scalp and/or mucosae of a human subject, comprise a therapeutically/cosmetically effective amount of at least one TNF-alpha antagonist.

Abstract: The present invention relates to the use of melatonin or analogues thereof in a composition as an agent for stabilizing hydrophilic gelling polymers. The invention relates more particularly to cosmetic or pharmaceutical compositions for topical use.

Abstract: The invention concerns a procedure for testing a potentially-active substance used in the hair-care field, this procedure being characterized by the fact that a fragment of at least one hair follicle without dermal papilla is isolated, this fragment being taken from beneath the point of attachment of the sebaceous gland and excluding the portion of the hair shaft located above the point of attachment of the sebaceous gland; that this fragment is incubated in a suitable culture medium for a sufficient period; that this fragment is placed in contact with a potentially-active hair-care substance; that a marker of the activity of said tested substance is quantitatively determined; and that the results of this determination are assessed as they compare to a control.

Abstract: An assay for determining whether a first substance is potentially suitable for use as an active agent in hair treating compositions is provided. This assay involves contacting a first substance having putative activity as an active agent for treating hair with plucked hair follicle contained in a culture medium and assaying for a second substance which is correlated to the potential efficacy of the first substance. This assay is particularly suitable for use in evaluating the potential efficacy of hair growth promoters, hair growth retardants, agents that affect hair color, agents that affect hair survival and agents that affect inflammation. This assay is especially suited for evaluating putative efficacy of agents for treatment and/or prevention of the inflammatory stages of alopecia. In particular, the compound to be quantitatively determined is a mediator of inflammation.

Abstract: The present invention relates to novel cosmetic and/or dermatological compositions comprising, in a cosmetically and/or dermatologically acceptable support, i) a dibenzoylmethane derivative, in particular 4-tert-butyl-4'-methoxydibenzoylmethane, ii) at least one specific 1,3,5-triazine derivative, and iii) at least one amide compound. These compositions are particularly photostable. The invention also relates to the use of these compositions in the cosmetic and/or dermatological fields, in particular, as a sunscreen.

Abstract: The present invention relates to novel cosmetic and/or dermatological compositions comprising, in a cosmetically and/or dermatologically acceptable support, i) a dibenzoylmethane derivative, in particular 4-tert-butyl-4'-methoxydibenzoylmethane, ii) at least one specific 1,3,5-triazine derivative, and iii) at least one dialkyl benzalmalonate. These compositions are particularly photostable.The invention also relates to the use of these compositions in the cosmetic and/or dermatological fields, in particular, as a sunscreen.

Abstract: The present invention relates to novel cosmetic and/or dermatological compositions comprising, in a cosmetically and/or dermatologically acceptable support, (i) a dibenzoylmethane derivative, in particular 4-tert-butyl-4'-methoxydibenzoylmethane, (ii) at least one specific 1,3,5-triazine derivative, and (iii) at least one silicone derivative containing a benzalmalonate function. These compositions are particularly photostable.The invention also relates to the use of these compositions in the cosmetic and/or dermatological fields, in particular, as a sunscreen.

Abstract: Dermatological/pharmaceutical compositions, well suited for the therapeutic treatment of and/or alleviation of pain associated with at least one of the skin disorders, zona, poszoster, scald or burns, demodicidosis, skin ulcer, fibrosis, hypertrophic cicatrization and/or acne rosacea, comprise an effective substance P antagonist amount of at least one salt of yttrium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, tin, zinc, manganese, cobalt, barium, strontium, or mixture thereof, in a dermatologically/pharmaceutically acceptable medium therefor.

Abstract: Topically applicable, water resistant cosmetic/dermatological compositions well suited for enhanced photoprotection of human skin and or/hair against the damaging effects of UV-A and UV-B irradiation, particularly solar radiation, comprise (I) a continuous aqueous dispersing phase, (ii) a first discontinuous globular oily dispersed phase O.sub.1, (iii) a second discontinuous globular oily dispersed phase O.sub.2, (iv) at least one O/W emulsifying agent, (v) at least one W/O emulsifying agent, (vi) a photoprotecting effective amount of at least one lipophilic UV screening agent, (vii) a photoprotecting effective amount of at least one hydrophilic screening agent, said first and second oily phases O.sub.1 and O.sub.2 being mutually incompatible, and the globules constituting said oily phase O.sub.1 having an average size which is different from the globules constituting said oily phase O.sub.2.